



Rec'd PCT/PTO 28 FEB 2005  
PCT/IB03 / 04194  
12.11.03



INVESTOR IN PEOPLE

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road

Newport,  
South Wales

NP10 8PP  
WPS

REC'D 27 NOV 2003

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

*P. Mahoney*

Dated 5 September 2003

**BEST AVAILABLE COPY**



The  
Patent  
Office

0281P02 E744837-1 000019  
700 0.00-0220198.6

1777

Request for grant of a patent

See the notes on the back of this form. You can also  
get an explanatory leaflet from the Patent Office to  
help you fill in this form)



The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference	P031652GB		
2. Patent application number (The Patent Office will fill in this part)	0220198.6		30 AUG 2002
3. Full name, address and postcode of the or of each applicant ( <u>underline all surnames</u> )	CHIRON SpA Via Fiorentina 1 53100 Siena Italy  Patents ADP number (if you know it) 8383416 001  If the applicant is a corporate body, give the country/state of its incorporation ITALY		
4. Title of the invention	Modified Saccharides, Conjugates Thereof, and their Manufacture		
5. Name of your agent (if you have one)	Carpmaels & Ransford		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	43 Bloomsbury Square London WC1A 2RA  Patents ADP number (if you know it) 83001		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:			
a) any applicant named in part 3 is not an inventor, or	Yes		
b) there is an inventor who is not named as an applicant, or			
c) any named applicant is a corporate body			

See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	20
Claim(s)	7
Abstract	1
Drawing(s)	3 + 3 <i>Mc</i>

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

*Carmichael & Ransford*  
Carmichael & Ransford

30th August 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Cameron J. Marshall

020-7242 8692

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

## MODIFIED SACCHARIDES, CONJUGATES THEREOF, AND THEIR MANUFACTURE

All documents cited herein are incorporated by reference in their entirety.

### TECHNICAL FIELD

5 This invention is in the field of saccharide chemistry and relates to modified saccharides, processes for their preparation, and conjugated derivatives. In particular, the invention relates to modified saccharides having a linker moiety, which may be used to link the saccharide to a protein.

### BACKGROUND ART

10 Polysaccharides are important biological molecules and they have been widely used in the pharmaceutical industry for the prevention and treatment of diseases. For example, capsular polysaccharides have been used for many years in vaccines against capsulated bacteria, such as meningococcus (*Neisseria meningitidis*), pneumococcus (*Streptococcus pneumoniae*) and Hib (*Haemophilus influenzae* type B).

15 To enhance immunogenicity of these polysaccharides, particularly in children, conjugate vaccines were developed. These comprise a capsular polysaccharide conjugated to a carrier protein [e.g. US 4,711,779; US 4,761,283; US patent 4,882,317]. The conjugated molecule may have the polysaccharide and protein linked directly or the polysaccharide and protein may be linked via a linker moiety.

20 Whilst different types of linker moieties have been developed, there is a need for new types of linker which are versatile and which can be coupled to the polysaccharide and protein using simple, reliable chemistry. There is a further need for new linkers which are non-toxic and which can be formed under mild conditions, avoiding the use of harsh reagents, such as strong acids and bases.

### DISCLOSURE OF THE INVENTION

#### 25 *Modified saccharides of the invention*

The invention provides a modified capsular saccharide comprising a moiety of the formula (I):



wherein:

A is a bond, -C(O)- or -OC(O)-

30 R<sup>1</sup> is selected from H or C<sub>1</sub>-C<sub>6</sub> alkyl;

L is a C<sub>1</sub>-C<sub>12</sub> alkylene group;

M is a masked aldehyde group.

The term "modified capsular saccharide" means a saccharide which is obtainable from a native capsular saccharide by suitable modification. Hence, the basic sequence of repeating monosaccharide units in the native capsular saccharide is retained in the modified capsular saccharides of the present invention.

5 The term "saccharide" encompasses both oligosaccharides (*e.g.* containing from 2 to 39 monosaccharide units) and polysaccharides (*e.g.* containing 40 or more monosaccharide units). As found naturally in bacteria, native capsular saccharides generally take the form of polysaccharides. Polysaccharides may be manipulated to give shorter oligosaccharides. Oligosaccharides may be obtained by purification and/or sizing of the native polysaccharide (*e.g.*  
10 by hydrolysis in mild acid, by heating, by sizing chromatography *etc.*).


Typically, the modified saccharides of the present invention are oligosaccharides. Oligosaccharides may be obtained from polysaccharides by any of the sizing methods described above.

The modified capsular saccharides of this invention are obtainable from native capsular  
15 saccharides. However, the present invention is not limited to modified saccharides obtained from native capsular saccharides. The modified capsular saccharides of the present invention may be obtained by other methods, such as total or partial synthesis.

In the modified capsular saccharides of the present invention, the moiety of formula (I) may be  
20 derived from a non-terminal hydroxyl group of a capsular saccharide or from a terminal anomeric hydroxyl group of a capsular saccharide.

When the moiety of formula (I) is derived from an anomeric hydroxyl group, it preferably replaces the anomeric hydroxyl group by, for example, a reductive amination reaction. Reductive amination reactions on terminal saccharide hydroxyl groups are well known in the art.

When the moiety of formula (I) is derived from a non-terminal hydroxyl group, it is preferably  
25 linked to the non-terminal hydroxyl group via, for example, a carbamate group. Hence, in a preferred embodiment, the modified capsular saccharide of the present invention comprises a moiety of the formula (Ia):




wherein  $\text{R}^1$ , L and M are as defined above.

30 Such compounds may be prepared by derivatizing a free hydroxyl group on a saccharide with, for example, CDI and then reacting the carbamate intermediate with an amine of formula:  $\text{HN}(\text{R}^1)-\text{L}-\text{M}$ .

Preferably,  $\text{R}^1$  is H. Preferably, L is a  $\text{C}_1$ - $\text{C}_6$  alkylene group. More preferably L is  $-\text{CH}_2\text{CH}_2\text{CH}_2-$ . The L group acts as a spacer when the moiety of formula (I) is used to link a

capsular saccharide to a protein in a saccharide-protein conjugate. It is found that a spacer group between the saccharide and the protein improves the stability of the conjugate.

The skilled person will be aware of many different functionalities which may be readily converted into an aldehyde group. Any such functionality would be suitable as the masked aldehyde group M. Preferably, the masked aldehyde group M is selected from



wherein:

$R^2$  is selected from H,  $C_1$ - $C_{12}$  alkyl,  $C_3$ - $C_{12}$  cycloalkyl,  $C_5$ - $C_{12}$  aryl or  $C_{5-12}$  aryl- $C_{1-6}$  alkyl (preferably  $R^2$  is not H);

X and Y are the same or different and are independently selected from O or S;

$R^3$  and  $R^4$  are independently selected from  $C_1$ - $C_{12}$  alkyl,  $C_3$ - $C_{12}$  cycloalkyl,  $C_5$ - $C_{12}$  aryl or  $C_{5-12}$  aryl- $C_{1-6}$  alkyl; or  $R^3$  and  $R^4$  are joined to form a  $C_3$ ,  $C_4$ ,  $C_5$ ,  $C_6$ ,  $C_7$  or  $C_8$  cycloalkyl ring containing the heteroatoms X and Y;

$R^5$  and  $R^6$  are independently selected from H,  $C_1$ - $C_{12}$  alkyl,  $C_3$ - $C_{12}$  cycloalkyl,  $C_5$ - $C_{12}$  aryl or  $C_{5-12}$  aryl- $C_{1-6}$  alkyl; or  $R^5$  and  $R^6$  are joined to form a  $C_3$  or  $C_{12}$  cycloalkyl ring;

$R^9$  and  $R^{10}$  are independently selected from H,  $C_1$ - $C_{12}$  alkyl,  $C_3$ - $C_{12}$  cycloalkyl,  $C_5$ - $C_{12}$  aryl or  $C_{5-12}$  aryl- $C_{1-6}$  alkyl; or  $R^9$  and  $R^{10}$  are joined to form a  $C_{3-12}$  cycloalkyl ring; and

$R^7$  and  $R^8$  are independently selected from  $C_1$ - $C_{12}$  alkyl or  $C_3$ - $C_{12}$  cycloalkyl groups.

The term "alkyl" is used herein to refer to alkyl groups in both straight and branched forms. The alkyl group may be interrupted with 1, 2 or 3 heteroatoms selected from -O-, -NH- or -S-. The alkyl group may also be interrupted with 1, 2 or 3 double and/or triple bonds. However, the term "alkyl" usually refers to alkyl groups having no heteroatom interruptions or double or triple bond interruptions. Where reference is made to  $C_{1-12}$  alkyl, it is meant the alkyl group may contain any number of carbon atoms between 1 and 12 (e.g.  $C_1$ ,  $C_2$ ,  $C_3$ ,  $C_4$ ,  $C_5$ ,  $C_6$ ,  $C_7$ ,  $C_8$ ,  $C_9$ ,  $C_{10}$ ,  $C_{11}$ ,  $C_{12}$ ). Similarly, where reference is made to  $C_{1-6}$  alkyl, it is meant the alkyl group may contain any number of carbon atoms between 1 and 6 (e.g.  $C_1$ ,  $C_2$ ,  $C_3$ ,  $C_4$ ,  $C_5$ ,  $C_6$ ).

The term "alkylene" is used herein to refer to alkylene groups in both straight and branched forms. The alkylene group may be interrupted with 1, 2 or 3 heteroatoms selected from -O-, -

NH- or -S-. The alkylene group may also be interrupted with 1, 2 or 3 double and/or triple bonds. However, the term "alkylene" usually refers to alkylene groups having no heteroatom interruptions or double or triple bond interruptions. Where reference is made to C<sub>1-12</sub> alkylene, it is meant the alkylene group may contain any number of carbon atoms between 1 and 12 (e.g. C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub>, C<sub>11</sub>, C<sub>12</sub>). Similarly, where reference is made to C<sub>1-6</sub> alkylene, it is meant the alkylene group may contain any number of carbon atoms between 1 and 6 (e.g. C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>).

The term "cycloalkyl" includes cycloalkyl, polycycloalkyl, and cycloalkenyl groups, as well as combinations of these with alkyl groups, such as cycloalkylalkyl groups. The cycloalkyl group may be interrupted with 1, 2 or 3 heteroatoms selected from -O-, -NH- or -S-. However, the term "cycloalkyl" usually refers to cycloalkyl groups having no heteroatom interruptions. Examples of cycloalkyl groups include cyclopentyl, cyclohexyl, cyclohexenyl, cyclohexylmethyl and adamantyl groups. Where reference is made to C<sub>3-12</sub> cycloalkyl, it is meant that the cycloalkyl group may contain any number of carbon atoms between 3 and 12 (e.g. C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub>, C<sub>11</sub>, C<sub>12</sub>).

The term "aryl" is used herein to refer to a carbon and hydrogen-containing aromatic group, such as phenyl or naphthyl. Where reference is made to C<sub>5-12</sub> aryl, it is meant that the aryl group may contain any number of carbon atoms between 5 and 12 (e.g. C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub>, C<sub>11</sub>, C<sub>12</sub>).

The term "C<sub>5-12</sub> aryl-C<sub>1-6</sub> alkyl" refers to groups such as benzyl, phenylethyl and naphthylmethyl. Preferably, the masked aldehyde is -CH(OH)CH<sub>2</sub>OH. Preferably, the modified capsular saccharide of the present invention comprises a moiety of formula -NH(CH<sub>2</sub>)<sub>3</sub>CH(OH)CH<sub>2</sub>OH, more preferably -OC(O)NH(CH<sub>2</sub>)<sub>3</sub>CH(OH)CH<sub>2</sub>OH.

The present invention provides compounds having a masked aldehyde group. The use of a masked aldehyde advantageously prevents unwanted side reactions during modification of the capsular saccharide. Moreover, when an aldehyde group is revealed, it may be used for reductive amination coupling with, for example, an amino group on a protein.


Generally, the moiety of formula (I) or (Ia) performs the function of providing a handle for subsequent reaction with an amine group of a protein. Hence, the moiety of formula (I) or (Ia) is usually used to form a linker group in a saccharide-protein conjugate.

However, the moiety of formula (I) or (Ia), preferably (Ia), may be used as a blocking group to stabilise the saccharide against degradation, especially degradation by acid hydrolysis. This further use of the moiety of formula (Ia) may be as an alternative to or in addition to its use as a linker group. The use of blocking groups to stabilise capsular saccharides is described in UK patent application no. 0207117.3.

When the moiety of formula (Ia) is used as a stabilizing blocking group, the modified saccharide preferably has more than one of these moieties to provide a stabilizing effect. For example, all or substantially all the monosaccharide units in the modified saccharide may have a blocking group comprising a group of formula (Ia). Alternatively, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the monosaccharide units may have a blocking group comprising a group of formula (I). At least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 monosaccharide units in the modified saccharide may have blocking groups.

Likewise, the number of blocking groups on each monosaccharide unit may vary. For example, the number of blocking groups on a monosaccharide unit may be 1, 2, 3, 4, 5 or 6, preferably 1 to 4, and more preferably 1 or 2.

Preferably, the modified saccharide of the present invention comprises a moiety of formula (I) or (Ia) which is then converted to an aldehyde. Hence, the present invention further provides a modified saccharide comprising a moiety of formulae (II) or, preferably, (IIa):



wherein A, R<sup>1</sup> and L are as defined above.

The conversion of masked aldehydes of formula (I) or (Ia) into aldehydes of formula (II) or (IIa) involves a simple synthetic step. For example, diols may be converted to aldehydes by oxidative cleavage (*e.g.* NaIO<sub>4</sub>, Pb(OAc)<sub>4</sub> *etc.*); alcohols may be converted to aldehydes by oxidation (*e.g.* Swern oxidation, Dess-Martin oxidation, Cr<sup>VI</sup> oxidations *etc.*); alkenes may be converted to aldehydes by oxidative double bond cleavage (*e.g.* ozonolysis followed by reductive work up, OsO<sub>4</sub>/NaIO<sub>4</sub>, OsO<sub>4</sub>/Pb(OAc)<sub>4</sub> *etc.*); acetals may be converted to aldehydes by acid hydrolysis; thioacetals may be converted to aldehydes by metal coordination, alkylation or oxidation (*e.g.* Hg<sup>II</sup>, Ag<sup>I</sup>, Ag<sup>II</sup>, Cu<sup>II</sup>, MeI, *N*-bromosuccinimide *etc.*); carboxylic esters, cyano compounds and Weinreb amides may be converted to aldehydes by a suitable reduction (*e.g.* NaBH<sub>4</sub>, DIBAL *etc.*).

Preferably, the masked aldehyde M is of formula -CH(OH)CH<sub>2</sub>OH. This diol may be advantageously converted to the corresponding aldehyde using a mild periodate oxidizing agent. It has been found that periodate oxidants, such as NaIO<sub>4</sub>, selectively form an aldehyde without affecting other sensitive functionalities on the capsular saccharide.



Hence, in a preferred embodiment, the modified saccharide comprises a moiety of formula: -NH(CH<sub>2</sub>)<sub>3</sub>C(O)H, more preferably -OC(O)NH(CH<sub>2</sub>)<sub>3</sub>C(O)H.



### ***Saccharide-protein conjugates***

The modified saccharide comprising a moiety of formula (II) or (IIa) may be used to couple the saccharide to a protein carrier. The coupling is preferably via reductive amination of an amino group on the protein with the aldehyde group on the modified saccharide comprising a moiety of formula (II) or (IIa). Reductive amination reactions are well known to be a reliable method for coupling saccharides and proteins. Usually, the reaction is performed using  $\text{NaBH}_3\text{CN}$ , although other suitable reductants may also be used.

Accordingly, the present invention provides a saccharide-protein conjugate wherein the saccharide and protein moieties are linked via a group of formula (IV) or, preferably, (IVa):



wherein A,  $\text{R}^1$  and L are as defined above. Preferably, L is  $\text{-(CH}_2\text{)}_4\text{-}$  in conjugates of the present invention. In a preferred embodiment, the saccharide and protein moieties are linked by a group of formula:  $\text{-OC(O)NH-(CH}_2\text{)}_4\text{-NH-}$ .

In the protein-saccharide conjugates of the present invention, the protein is preferably a bacterial toxin or toxoid, more preferably a diphtheria or tetanus toxin or toxoid. These are commonly used in conjugate vaccines. The CRM<sub>197</sub> diphtheria toxoid is particularly preferred [1]. Other suitable carrier proteins include the *N.meningitidis* outer membrane protein [2], synthetic peptides [3,4], heat shock proteins [5,6], pertussis proteins [7,8], protein D from *H.influenzae* [9], cytokines [10], lymphokines [10], hormones [10], growth factors [10], toxin A or B from *C.difficile* [11], iron-uptake proteins [12] etc. It is possible to use mixtures of carrier proteins.


After conjugation, free and conjugated saccharides can be separated. There are many suitable methods, including hydrophobic chromatography, tangential ultrafiltration, diafiltration etc. [see also refs. 13, 14 etc.].

A single carrier protein may carry multiple different saccharides [15].


### ***Modified Neisseria meningitidis serogroup A saccharides***

In all the embodiments described above, the modified capsular saccharide is preferably a modified *Neisseria meningitidis* saccharide. More preferably, the modified capsular saccharide is a modified *Neisseria meningitidis* serogroup A saccharide.

The *Neisseria meningitidis* serogroup A saccharide has the following structure:




Accordingly, the present invention provides a saccharide of formula:




wherein:

T is of the formula (A) or (B):



(A)



(B)

5 n is an integer from 1 to 100;

each Z group is independently selected from -OH, -OAc, -OC(O)N(R<sup>1</sup>)-L-M or -OC(O)N(R<sup>1</sup>)-L-C(O)H;

each Q group is independently selected from -OH, -OAc, -OC(O)N(R<sup>1</sup>)-L-M or -OC(O)N(R<sup>1</sup>)-L-C(O)H;

10 W is selected from -OH, -OAc, -OC(O)N(R<sup>1</sup>)-L-M or -OC(O)N(R<sup>1</sup>)-L-C(O)H (preferably W is OH);

V is -N(R<sup>1</sup>)-L-M or -N(R<sup>1</sup>)-L-C(O)H;

wherein  $R^1$ , L and M are as defined above, and provided that the saccharide comprises at least one moiety of the formula  $-N(R^1)-L-M$ ,  $-N(R^1)-L-C(O)H$ ,  $-OC(O)N(R^1)-L-M$  or  $-OC(O)N(R^1)-L-C(O)H$ .

Preferably, n is an integer from 15 to 25.

- 5 Preferably, T is of the formula (A). Preferably the saccharide comprises at least one moiety of the formula  $-OC(O)N(R^1)-L-M$  or  $-OC(O)N(R^1)-L-C(O)H$ .

Preferably, Q and Z are a mixture of OH and OAc groups in essentially the same relative proportions as in the native *Neisseria meningitidis* serogroup A saccharide, with the exception that one of the Q or Z groups, preferably one of the Q groups, is  
10  $-OC(O)N(R^1)-L-M$  or  $-OC(O)N(R^1)-L-C(O)H$ .

**Process for producing modified saccharides**

This invention further provides a process for modifying a capsular saccharide comprising the steps of:

- 15 (a) providing a capsular saccharide having a hydroxyl group;  
(b) reacting the hydroxyl group with a bifunctional reagent in an organic solvent;  
(c) reacting the product of step (b) with an amino compound of formula (III):



wherein  $R^1$ , L and M are as defined above.

20 The capsular saccharide may be a native capsular saccharide (oligosaccharide or polysaccharide). Alternatively, the capsular saccharide may be, for example, a de-O-acetylated capsular saccharide, a blocked capsular saccharide (as described in UK patent application no. 0207117.3) or a capsular saccharide having a terminal amino group (e.g. obtained by reductive amination).

25 The term "bifunctional reagent" means any reagent which is capable of performing the dual functions of (i) providing a first electrophilic carbon atom for coupling with the hydroxyl group(s) on the saccharide; and (ii) providing a second electrophilic carbon atom for coupling with the amino group used in step (b2). Generally, the second electrophilic carbon atom is regenerated from the first electrophilic carbon atom during step (b). The bifunctional reagent provides a  $-C(O)-$  linkage between the polysaccharide and the amino compound.

30 Bifunctional reagents for use in the present invention include, but are not limited to, 1,1'-carbonyldiimidazole (CDI), carbonyl di-1,2,4-triazole (CDT), carbonyl di-1,2,3-benzotriazole (CDB), diphenylcarbonate, cyanogen bromide, phosgene or triphosgene. The skilled person will be aware of other bifunctional reagents which can perform the same function



In a preferred embodiment, there is provided a process for modifying a saccharide as described above which further comprises the steps of (d) unmasking the masked aldehyde group M, thereby providing an aldehyde compound; and (e) linking the aldehyde compound to a protein by a reductive amination reaction. In this process process, the masked aldehyde group M is preferably  $-\text{CH}(\text{OH})\text{CH}_2\text{OH}$ , the unmasking step is preferably a periodate cleavage, and the reducing agent in the reductive amination reaction is preferably  $\text{NaBH}_3\text{CN}$ . This preferred embodiment is shown in Figure 1. In Figure 1, PS represents a polysaccharide or oligosaccharide derived from native *Neisseria meningitidis* serogroup A saccharide.

#### ***Pharmaceutical compositions and methods***

The invention provides a pharmaceutical composition comprising (a) a modified saccharide of the invention and/or a conjugate of the invention, and (b) a pharmaceutically acceptable carrier.

Where a conjugate is present, the composition may also comprise free carrier protein [16].

'Pharmaceutically acceptable carriers' include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, trehalose [17] lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. The vaccines may also contain diluents, such as water, saline, glycerol, *etc.* Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences.

Typically, the compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect. Direct delivery of the compositions will generally be parenteral (*e.g.* by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue). The compositions can also be administered into a lesion. Other modes of administration include oral and pulmonary administration, rectal (suppositories), and transdermal or transcutaneous applications [*e.g.* ref. 18], needles, and hypodermic sprays. Dosage treatment may be a single dose or a multiple dose schedule (*e.g.* including booster doses).

The composition of the invention is preferably sterile, buffered, and/or pyrogen-free.

The composition is preferably an immunogenic composition (*e.g.* a vaccine). Vaccines based on saccharides or saccharide-protein conjugates are well known in the art.

Immunogenic compositions comprise an immunologically effective amount of saccharide antigen, as well as any other of other specified components, as needed. By 'immunologically effective amount', it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (*e.g.* non-human primate, primate, *etc.*), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Dosage treatment may be a single dose schedule or a multiple dose schedule (*e.g.* including booster doses). The vaccine may be administered in conjunction with other immunoregulatory agents.

The immunogenic composition may include an adjuvant. Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (A) aluminium compounds (*e.g.* aluminium hydroxide, aluminium phosphate, aluminium hydroxyphosphate, oxyhydroxide, orthophosphate, sulphate *etc.* [*e.g.* see chapters 8 & 9 of ref. 19]), or mixtures of different aluminium compounds, with the compounds taking any suitable form (*e.g.* gel, crystalline, amorphous *etc.*), and with adsorption being preferred; (B) MF59 (5% Squalene, 0.5% Tween 80, and 0.5% Span 85, formulated into submicron particles using a microfluidizer) [see Chapter 10 of ref. 19; see also ref. 20]; (C) liposomes [see Chapters 13 and 14 of ref. 19]; (D) ISCOMs [see Chapter 23 of ref. 19], which may be devoid of additional detergent [21]; (E) SAF, containing 10% Squalene, 0.4% Tween 80, 5% pluronic-block polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion [see Chapter 12 of ref. 19]; (F) Rib<sup>i</sup>™ adjuvant system (RAS), (Ribi Immunochem) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™); (G) saponin adjuvants, such as QuilA or QS21 [see Chapter 22 of ref. 19], also known as Stimulon™; (H) chitosan [*e.g.* 22]; (I) complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA); (J) cytokines, such as interleukins (*e.g.* IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, *etc.*), interferons (*e.g.* interferon-γ), macrophage colony stimulating factor, tumor necrosis factor, *etc.* [see Chapters 27 & 28 of ref. 19]; (K) microparticles (*i.e.* a particle of ~100nm to ~150μm in diameter, more preferably ~200nm to ~30μm in diameter, and most preferably ~500nm to ~10μm in diameter) formed from materials that are biodegradable and non-toxic (*e.g.* a poly(α-hydroxy acid), a polyhydroxybutyric acid, a polyorthoester, a polyanhydride, a polycaprolactone *etc.*); (L) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) [*e.g.* chapter 21 of ref. 19]; (M) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions [23]; (N) oligonucleotides comprising CpG

- a protein antigen from *N.meningitidis* serogroup B, such as those in refs. 43 to 49, with protein '287' (see below) and derivatives (e.g. 'ΔG287') being particularly preferred.
- an outer-membrane vesicle (OMV) preparation from *N.meningitidis* serogroup B, such as those disclosed in refs. 50, 51, 52, 53 etc.
- 5 - a saccharide antigen from *N.meningitidis* serogroup C, such as the oligosaccharide disclosed in ref. 54 from serogroup C [see also ref. 55].
  - a saccharide antigen from *Streptococcus pneumoniae* [e.g. 56, 57, 58].
  - an antigen from hepatitis A virus, such as inactivated virus [e.g. 59, 60].
  - an antigen from hepatitis B virus, such as the surface and/or core antigens [e.g. 60, 61].
- 10 - an antigen from hepatitis C virus [e.g. 62].
  - an antigen from *Bordetella pertussis*, such as pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) from *B.pertussis*, optionally also in combination with pertactin and/or agglutinogens 2 and 3 [e.g. refs. 63 & 64].
  - a diphtheria antigen, such as a diphtheria toxoid [e.g. chapter 3 of ref. 65] e.g. the CRM<sub>197</sub> mutant [e.g. 66].
- 15 - a tetanus antigen, such as a tetanus toxoid [e.g. chapter 4 of ref. 65].
  - a saccharide antigen from *Haemophilus influenzae* B [e.g. 55].
  - an antigen from *N.gonorrhoeae* [e.g. 43, 44, 45].
  - an antigen from *Chlamydia pneumoniae* [e.g. 67, 68, 69, 70, 71, 72, 73].
- 20 - an antigen from *Chlamydia trachomatis* [e.g. 74].
  - an antigen from *Porphyromonas gingivalis* [e.g. 75].
  - polio antigen(s) [e.g. 76, 77] such as IPV or OPV.
  - rabies antigen(s) [e.g. 78] such as lyophilised inactivated virus [e.g. 79, RabAvert™].
  - measles, mumps and/or rubella antigens [e.g. chapters 9, 10 & 11 of ref. 65].
- 25 - influenza antigen(s) [e.g. chapter 19 of ref. 65], such as the haemagglutinin and/or neuraminidase surface proteins.
  - an antigen from *Moraxella catarrhalis* [e.g. 80].
  - an antigen from *Streptococcus agalactiae* (group B streptococcus) [e.g. 81, 82].
  - a saccharide antigen from *Streptococcus agalactiae* (group B streptococcus).
- 30 - an antigen from *Streptococcus pyogenes* (group A streptococcus) [e.g. 82, 83, 84].
  - an antigen from *Staphylococcus aureus* [e.g. 85].
  - an antigen from *Bacillus anthracis* [e.g. 86, 87, 88].
  - an antigen from a virus in the flaviviridae family (genus flavivirus), such as from yellow fever virus, Japanese encephalitis virus, four serotypes of Dengue viruses, tick-borne encephalitis virus, West Nile virus.
- 35



- a pestivirus antigen, such as from classical porcine fever virus, bovine viral diarrhoea virus, and/or border disease virus.
- a parvovirus antigen *e.g.* from parvovirus B19.
- a prion protein (*e.g.* the CJD prion protein)
- 5 - an amyloid protein, such as a beta peptide [89]
- a cancer antigen, such as those listed in Table 1 of ref. 90 or in tables 3 & 4 of ref. 91.

The composition may comprise one or more of these further antigens.

Toxic protein antigens may be detoxified where necessary (*e.g.* detoxification of pertussis toxin by chemical and/or genetic means [64]).

- 10 Where a diphtheria antigen is included in the composition it is preferred also to include tetanus antigen and pertussis antigens. Similarly, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similarly, where a pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens.

Antigens are preferably adsorbed to an aluminium salt.

- 15 Antigens in the composition will typically be present at a concentration of at least 1µg/ml each. In general, the concentration of any given antigen will be sufficient to elicit an immune response against that antigen.

- As an alternative to using proteins antigens in the composition of the invention, nucleic acid encoding the antigen may be used [*e.g.* refs. 92 to 100]. Protein components of the compositions  
20 of the invention may thus be replaced by nucleic acid (preferably DNA *e.g.* in the form of a plasmid) that encodes the protein.

- The invention also provides a method for raising an antibody response in a mammal, comprising administering a pharmaceutical composition of the invention to the mammal. The mammal is preferably a human. The human may be an adult or, preferably, a child. The antibody response is  
25 preferably protective against infection by *N.meningitidis* serogroup A.

The invention also provides a method for immunising a mammal, comprising administering a pharmaceutical composition of the invention to the mammal.

This invention also provides a modified saccharide of the invention, or a conjugate of the invention, for use as a medicament.

- 30 The invention also provides the use of a modified saccharide of the invention, or of a conjugate of the invention, in the manufacture of a medicament for preventing or treating a disease caused by capsulate bacteria. Diseases caused by *Neisseria* include meningitis, septicaemia and gonorrhoea. Diseases caused by *H.influenzae* include otitis media, bronchitis, pneumonia,

**REFERENCES** (the contents of which are incorporated herein in full)

- [1] *Research Disclosure*, 453077 (Jan 2002)
- [2] EP-A-0372501
- [3] EP-A-0378881
- [4] EP-A-0427347
- [5] WO93/17712
- [6] WO94/03208
- [7] WO98/58668
- [8] EP-A-0471177
- [9] WO00/56360
- [10] WO91/01146
- [11] WO00/61761
- [12] WO01/72337
- [13] Lei *et al.* (2000) *Dev Biol (Basel)* 103:259-264
- [14] WO00/38711
- [15] WO99/42130
- [16] WO96/40242
- [17] WO00/56365
- [18] WO98/20734
- [19] *Vaccine design: the subunit and adjuvant approach*, eds. Powell & Newman, Plenum Press 1995 (ISBN 0-306-44867-X).
- [20] WO90/14837.
- [21] WO00/07621.
- [22] WO99/27960.
- [23] European patent applications 0835318, 0735898 and 0761231.
- [24] Krieg (2000) *Vaccine* 19:618-622; Krieg (2001) *Curr opin Mol Ther* 2001 3:15-24; WO96/02555, WO98/16247, WO98/18810, WO98/40100, WO98/55495, WO98/37919 and WO98/52581 *etc.*
- [25] WO99/52549.
- [26] WO01/21207.
- [27] WO01/21152.
- [28] WO00/62800.
- [29] WO00/23105.
- [30] WO99/11241.
- [31] WO98/57659.
- [32] Del Giudice *et al.* (1998) *Molecular Aspects of Medicine*, vol. 19, number 1.
- [33] Covacci & Rappuoli (2000) *J. Exp. Med.* 19:587-592.
- [34] WO93/18150.
- [35] Covacci *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90: 5791-5795.
- [36] Tummuru *et al.* (1994) *Infect. Immun.* 61:1799-1809.
- [37] Marchetti *et al.* (1998) *Vaccine* 16:33-37.
- [38] Telford *et al.* (1994) *J. Exp. Med.* 179:1653-1658.
- [39] Evans *et al.* (1995) *Gene* 153:123-127.

- [85] Kuroda *et al.* (2001) *Lancet* 357(9264):1225-1240; see also pages 1218-1219.
- [86] Robinson & Torres (1997) *Seminars in Immunology* 9:271-283.
- [87] Donnelly *et al.* (1997) *Annu Rev Immunol* 15:617-648.
- [88] Scott-Taylor & Dalglish (2000) *Expert Opin Investig Drugs* 9:471-480.
- [89] Apostolopoulos & Plebanski (2000) *Curr Opin Mol Ther* 2:441-447.
- [90] Ilan (1999) *Curr Opin Mol Ther* 1:116-120.
- [91] Dubensky *et al.* (2000) *Mol Med* 6:723-732.
- [92] Robinson & Pertmer (2000) *Adv Virus Res* 55:1-74.
- [93] Donnelly *et al.* (2000) *Am J Respir Crit Care Med* 162(4 Pt 2):S190-193.
- [94] Davis (1999) *Mt. Sinai J. Med.* 66:84-90.

CLAIMS

1. A modified capsular saccharide comprising a moiety of the formula (I):



wherein:

A is a bond,  $-C(O)-$  or  $-OC(O)-$

$R^1$  is selected from H or  $C_1-C_6$  alkyl;

10 L is a  $C_1-C_{12}$  alkylene group;

M is a masked aldehyde group.


2. The modified capsular saccharide of claim 1 wherein A is  $-OC(O)-$ .

- 15 3. The modified capsular saccharide of claim 1 or 2 wherein  $R^1$  is H.

4. The modified capsular saccharide of any preceding claim wherein L is a  $C_1-C_6$  alkylene group.

- 20 5. The modified capsular saccharide of claim 4 wherein L is  $-\text{CH}_2\text{CH}_2\text{CH}_2-$ .

6. The modified capsular saccharide of any preceding claim wherein the masked aldehyde is selected from:



wherein:

$R^2$  is selected from H,  $C_1-C_{12}$  alkyl,  $C_3-C_{12}$  cycloalkyl,  $C_5-C_{12}$  aryl or  $C_{5-12}$  aryl- $C_{1-6}$  alkyl;

X and Y are the same or different and are independently selected from O or S;

$R^3$  and  $R^4$  are independently selected from  $C_1$ - $C_{12}$  alkyl,  $C_3$ - $C_{12}$  cycloalkyl,  $C_5$ - $C_{12}$  aryl or  $C_5$ - $C_{12}$  aryl- $C_{1-6}$  alkyl; or  $R^3$  and  $R^4$  are joined to form a  $C_3$ ,  $C_4$ ,  $C_5$ ,  $C_6$ ,  $C_7$  or  $C_8$  cycloalkyl ring containing the heteroatoms X and Y;

$R^5$  and  $R^6$  are independently selected from H,  $C_1$ - $C_{12}$  alkyl,  $C_3$ - $C_{12}$  cycloalkyl,  $C_5$ - $C_{12}$  aryl or  $C_5$ - $C_{12}$  aryl- $C_{1-6}$  alkyl; or  $R^5$  and  $R^6$  are joined to form a  $C_3$  or  $C_{12}$  cycloalkyl ring;

$R^9$  and  $R^{10}$  are independently selected from H,  $C_1$ - $C_{12}$  alkyl,  $C_3$ - $C_{12}$  cycloalkyl,  $C_5$ - $C_{12}$  aryl or  $C_5$ - $C_{12}$  aryl- $C_{1-6}$  alkyl; or  $R^9$  and  $R^{10}$  are joined to form a  $C_3$  to  $C_{12}$  cycloalkyl ring; and

$R^7$  and  $R^8$  are independently selected from  $C_1$ - $C_{12}$  alkyl or  $C_3$ - $C_{12}$  cycloalkyl groups.

10 7. The modified capsular saccharide of claim 6 wherein the masked aldehyde is  $-\text{CH}(\text{OH})\text{CH}_2\text{OH}$ .


8. The modified capsular saccharide of claim 1 or claims 3 to 7 comprising a moiety of the formula:  $-\text{NH}(\text{CH}_2)_3\text{CH}(\text{OH})\text{CH}_2\text{OH}$ .

15

9. The modified saccharide of claims 1 to 7 comprising a moiety of the formula:  $-\text{OC}(\text{O})\text{NH}(\text{CH}_2)_3\text{CH}(\text{OH})\text{CH}_2\text{OH}$ .

10. A modified capsular saccharide comprising a moiety of the formula (II):

20



wherein A,  $\text{R}^1$  and L are as defined in any one of claims 1 to 5.

25 11. The modified capsular saccharide of claim 10 wherein A is  $-\text{OC}(\text{O})-$ .

12. The modified capsular saccharide of claim 10 comprising a moiety of the formula:  $-\text{NH}(\text{CH}_2)_3\text{C}(\text{O})\text{H}$ .

30 13. The modified capsular saccharide of claims 10 or 11 comprising a moiety of the formula:  $-\text{OC}(\text{O})\text{NH}(\text{CH}_2)_3\text{C}(\text{O})\text{H}$

each Q group is independently selected from -OH, -OAc, -OC(O)N(R<sup>1</sup>)-L-M or -OC(O)N(R<sup>1</sup>)-L-C(O)H;

W is selected from -OH, -OAc, -OC(O)N(R<sup>1</sup>)-L-M or -OC(O)N(R<sup>1</sup>)-L-C(O)H;

V is -N(R<sup>1</sup>)-L-M or -N(R<sup>1</sup>)-L-C(O)H;

- 5 wherein R<sup>1</sup>, L and M are as defined above, and provided that the saccharide comprises at least one moiety of the formula -N(R<sup>1</sup>)-L-M, -N(R<sup>1</sup>)-L-C(O)H, -OC(O)N(R<sup>1</sup>)-L-M or -OC(O)N(R<sup>1</sup>)-L-C(O)H.

16. The saccharide of claim 15 wherein n is an integer from 15 to 25.

10

17. The saccharide of claim 15 or 16 wherein T is of the formula (A).


18. The saccharide of claims 15 to 17 wherein Q and Z are a mixture of OH and OAc groups in essentially the same relative proportions as in the native *Neisseria meningitidis* serogroup A saccharide, with the exception that one of the Q or Z groups is -OC(O)N(R<sup>1</sup>)-L-M or -OC(O)N(R<sup>1</sup>)-L-C(O)H.
- 15

19. The saccharide of claim 18 wherein one of the Q groups is -OC(O)N(R<sup>1</sup>)-L-M or -OC(O)N(R<sup>1</sup>)-L-C(O)H.

20

20. A process for modifying a capsular saccharide comprising the steps of:

- (a) providing a capsular saccharide having a hydroxyl group;
- (b) reacting the hydroxyl group with a bifunctional reagent in an organic solvent;
- 25 (c) reacting the product of step (b) with an amino compound of formula (III):



wherein R<sup>1</sup>, L and M are as defined in any one of claims 1 to 7.

30

21. The process of claim 20 wherein the capsular saccharide is *Neisseria meningitidis* serogroup A saccharide.

22. The process of claim 20 or 21, wherein the organic solvent is an aprotic solvent.
23. The process of claim 22 wherein the aprotic solvent is selected from dimethylsulfoxide (DMSO), dimethylformamide (DMF), formamide, 5 hexamethylphosphoramide (HMPA), hexamethylphosphorus triamide (HMPT), 1,3-dimethyl-3,4,5,6-tetrahydro-2(1*H*)-pyrimidinone (DMPU) or dimethylacetamide (DMAC).
24. The process of claims 22 or 23 wherein the aprotic solvent is DMSO.
- 10 25. The process of claims 20 to 24 wherein the bifunctional reagent is selected from 1,1'-carbonyldiimidazole (CDI), carbonyl di-1,2,4-triazole (CDT), carbonyl di-1,2,3-benzotriazole (CDB), diphenylcarbonate, cyanogen bromide, phosgene or triphosgene.
26. The process of claim 25 wherein the bifunctional reagent is CDI.
- 15 27. The process of claims 20 to 26 wherein the amino compound in step (c) is  $\text{H}_2\text{N}(\text{CH}_2)_3\text{CH}(\text{OH})\text{CH}_2\text{OH}$ .
28. The process of claims 20 to 27, further comprising the step of (d) unmasking the 20 masked aldehyde group M, thereby providing an aldehyde compound.
29. The process of claim 28 wherein the masked aldehyde group M is  $-\text{CH}(\text{OH})\text{CH}_2\text{OH}$  and the unmasking step is a periodate cleavage.
- 25 30. The process of claim 28 or 29, further comprising the step of (e) linking the aldehyde compound to a protein by a reductive amination reaction.
31. The process of claim 30 wherein the reducing agent in the reductive amination reaction is  $\text{NaBH}_3\text{CN}$ .
- 30 32. A process for modifying a *Neisseria meningitidis* serogroup A saccharide saccharide comprising the steps of:
- (a) providing a *Neisseria meningitidis* serogroup A saccharide;

- (b) reacting a hydroxyl group on the saccharide with CDI in DMSO solvent;
- (c) reacting the product of step (b) with  $\text{H}_2\text{N}(\text{CH}_2)_3\text{CH}(\text{OH})\text{CH}_2\text{OH}$ ;
- (d) cleaving the product of step (c) with periodate, thereby providing an aldehyde compound; and
- (e) linking the aldehyde compound of step (d) to a protein by a reductive amination reaction using  $\text{NaBH}_3\text{CN}$ .

33. A saccharide-protein conjugate wherein the saccharide and protein moieties are linked via a group of formula (IV):



wherein A,  $\text{R}^1$  and L are as defined in claims 1 to 4.

34. A saccharide-protein conjugate wherein  $\text{R}^1$  is H, A is  $-\text{OC}(\text{O})-$  and L is  $-(\text{CH}_2)_4-$ .

35. The conjugate of claim 33 or 34 wherein the saccharide is a *Neisseria meningitidis* serogroup A saccharide.

36. The process of claims 30 to 32 or the conjugate of claims 33 to 35 wherein the protein is a bacterial toxin or toxoid.

37. The process or conjugate of claim 36 wherein the bacterial toxin or toxoid is diphtheria toxin or toxoid.

38. The process of claims 30 to 32 or the conjugate of claim 36 wherein the bacterial toxin or toxoid is CRM<sub>197</sub>.

39. A pharmaceutical composition comprising a saccharide-protein conjugate according to any one of claims 33 to 38 and/or a modified saccharide according to any one of claims 1 to 19, and (b) a pharmaceutically acceptable carrier.



40. The composition of claim 39, further comprising a vaccine adjuvant.

41. The composition of claim 40, which is a vaccine against a disease caused by *Neisseria meningitidis*.

5

42. A method for raising an antibody response in a mammal, comprising administering the pharmaceutical composition of claim 39 to the mammal.

43. The conjugate of any one of claims 33 to 38 or the saccharide of claims 1 to 19 for  
10 use as a medicament.

44. The use of the conjugate of any one of claims 33 to 38 or a saccharide of claims 1 to 19 in the manufacture of a medicament for preventing or treating a disease caused by one or more capsulate bacteria.

15

45. The use of claim 44, wherein the disease is bacterial meningitis.

**ABSTRACT**

Saccharide-protein conjugates having a new type of linker are described. The conjugates comprising the new linker are prepared from modified saccharides comprising a moiety of  
5 the formula (I):



wherein:


10 A is a bond, -C(O)- or -OC(O)-


R<sup>1</sup> is selected from H or C<sub>1</sub>-C<sub>6</sub> alkyl;


L is a C<sub>1</sub>-C<sub>12</sub> alkylene group;

M is a masked aldehyde group.

The new linker is especially useful for preparing conjugates of *Neisseria meningitidis*  
15 serogroup A saccharide. Conjugates having this new linker have improved immunogenicity compared to other types of conjugates.

**FIGURE 1**

**FIGURE 2**

**FIGURE 3**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record.**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**